


# Access to other (non-oncology) medicines

Based on medicine and vaccine indications approved by the European Medicines Agency (EMA) between 2022 – Q2 2026, only 43% are currently available to patients on the NHS



## Understanding the graphic

### Terminology used

- **EMA-approved indications** = All indications approved by Europe's regulator (EMA) in the specified timeframe, excluding minor extensions such as small changes to age ranges or patient weight limits.
- **MHRA-approved indications** = All indications from the EMA list which are also approved by the UK's regulator (MHRA).
- **No MHRA approval** = Indications which have a licence from the EMA for use in Europe, however, do not have a licence from the MHRA for use in the UK
- **NICE in development** = Indications that are awaiting assessment or are in development by NICE as of the end of the specified timeframe.
- **Non-NICE access, including specialised commissioning** = Indications available in England through funding routes outside the usual NICE process, including NHS England specialised commissioning
- **Completed NICE appraisal** = Indications that have been considered by NICE.
- **No UK data** = Includes indications which have been approved by the MHRA, but have not been assessed by NICE and show evidence of active assessment by NICE, and show no evidence of any UK sales. On that basis, these indications are assumed not to be available to NHS patients, with no future plans to make them available.
- **Recommended for use on the NHS** = Indications that NICE recommended for use on the NHS, either in full or for a narrower group of patients.
- **Not recommended** = Indications that NICE decided not to recommend for use on the NHS.
- **Terminated** = Indications where the NICE appraisal was stopped before a final recommendation was made or no submission was made by the company.

- **Full recommendation** = Indications recommended by NICE for use in line with the full marketing authorisation.
- **Optimised** = Indications recommended by NICE for only part of the licensed patient population.
- **Footnotes:**
  - Indications are the different diseases or groups of patients within a disease which a medicine can be used for. Different indications for a medicine tend to be approved at different times, hence the graphic above considers the data on an indication, rather than medicine level, to provide as detailed a picture as possible.
  - \*The graphic assesses approvals by NICE and therefore focuses on access to medicines in England. For a medicine to be available in Scotland, it must be approved by the Scottish Medicines Consortium (SMC). For a medicine to be available in Wales and Northern Ireland, often a NICE recommendation suffices, however the All-Wales Medicines Strategy Group (AWMSG) also carry out their own appraisals on certain medicines that NICE has not evaluated.

ABPI worked in collaboration with the Office of Health Economics (OHE) to extract the data for the infographics, via the OHE Medicines Tracker.